By Editor • August 27, 2026 • 1 min read
The FDA has granted approval to Roivant and its subsidiary Priovant for a new medication aimed at treating dermatomyositis, an uncommon autoimmune condition.
Brepocitinib, branded as Lisraya, is a once-daily pill designed to alleviate symptoms of this disease, which impacts 40,000 to 70,000 Americans.
Source: www.statnews.com
By Editor • August 28, 2026 • 1 min read
PIMS begins referring serious gynaecological cases to nearby hospitals following a tragic incident that claimed 14 newborns' lives.
Read moreBy Editor • August 28, 2026 • 1 min read
The FDA has approved updated Covid-19 vaccines targeting the XFG variant, allowing manufacturers to start shipping doses amid insurance coverage uncertainties.
Read moreBy Editor • August 28, 2026 • 2 min read
Pennsylvania's announcement of measles-related deaths raises concerns over potential miscommunication and its impact on vaccination debates.
Read more
